Efficacy of the Management of Node Negative Early Stage Breast Cancer Using 1% Methylene Blue in Sentinel Lymph Node Biopsy:prospective study, kasrAlaini University Hospital
Khallaf, E., Abouelnaga, H., Dowara, S., Daoud, M., Lolah, W., Mokhtar, S. (2021). Efficacy of the Management of Node Negative Early Stage Breast Cancer Using 1% Methylene Blue in Sentinel Lymph Node Biopsy:prospective study, kasrAlaini University Hospital. EKB Journal Management System, 64(12), 7431-7439. doi: 10.21608/ejchem.2021.93012.4398
Emad Khallaf; hasan Abouelnaga; Salma Dowara; Mohammed A. Daoud; Wael Lolah; Sherif M. Mokhtar. "Efficacy of the Management of Node Negative Early Stage Breast Cancer Using 1% Methylene Blue in Sentinel Lymph Node Biopsy:prospective study, kasrAlaini University Hospital". EKB Journal Management System, 64, 12, 2021, 7431-7439. doi: 10.21608/ejchem.2021.93012.4398
Khallaf, E., Abouelnaga, H., Dowara, S., Daoud, M., Lolah, W., Mokhtar, S. (2021). 'Efficacy of the Management of Node Negative Early Stage Breast Cancer Using 1% Methylene Blue in Sentinel Lymph Node Biopsy:prospective study, kasrAlaini University Hospital', EKB Journal Management System, 64(12), pp. 7431-7439. doi: 10.21608/ejchem.2021.93012.4398
Khallaf, E., Abouelnaga, H., Dowara, S., Daoud, M., Lolah, W., Mokhtar, S. Efficacy of the Management of Node Negative Early Stage Breast Cancer Using 1% Methylene Blue in Sentinel Lymph Node Biopsy:prospective study, kasrAlaini University Hospital. EKB Journal Management System, 2021; 64(12): 7431-7439. doi: 10.21608/ejchem.2021.93012.4398

Efficacy of the Management of Node Negative Early Stage Breast Cancer Using 1% Methylene Blue in Sentinel Lymph Node Biopsy:prospective study, kasrAlaini University Hospital

Egyptian Journal of Chemistry
Article 60, Volume 64, Issue 12, December 2021, Page 7431-7439  XML PDF (705.67 K)
Document Type: Original Article
DOI: 10.21608/ejchem.2021.93012.4398
View on SCiNiTO View on SCiNiTO
Authors
Emad Khallaf1; hasan Abouelnaga1; Salma Dowara1; Mohammed A. Daoud email orcid 2; Wael Lolah1; Sherif M. Mokhtar1
1MD
2FRCSEd,MD,FEBS,MRCS,MSc
Abstract
Background:Accurate staging and proper management of axillary lymph nodes are important for the treatment of breast cancer. Sentinel lymph node biopsy (SLNB) provides accurate assessment of nodal status.
Aimof work:Evaluation the safety, the accuracy and the cost of the application of SLNB using methylene blue 1% (MB 1%) in cases of node negative early stage breast cancer.
Patients and methods:This study was conducted at Kasr Al-Ainy university Hospitals, Faculty of Medicine, Cairo University. Fifty-two female patients with node negative early stage breast cancer who agreed on undergoing breast conservative surgery( BCS), SLNB using 1% methylene blue and frozen section examination then managed according to ACOSOG Z0011 criteria .
Results:Identification in 50 surgical specimens (identification rate 96.15%). By evaluating frozen section examination of the lymph nodes in relation to paraffin section examination we found that the sensitivity of the frozen section examination was 100% and specificity was 97.5% with positive predictive value 90.9%, negative predictive value 100% and overall accuracy was 98%.
Conclusion:One % MB dye is very effective as a single agent in SLNB in node negative early stage breast cancer with very high identification rate compared to patent blue and radiocolloids. Implementation of ACOSOG Z0011 criteria proved its validity throughout our study as average 12 months follow up showed no locoregional recurrence
Keywords
Sentinel lymph node biopsy; node negative; methylene blue; early stage breast cancer
Statistics
Article View: 263
PDF Download: 166